Table 1:
Demographic, clinical, and pathological measures between pathology groups
| No CTE/No AD | AD | CTE | CTE & AD | p-value | |
|---|---|---|---|---|---|
| Sample size (n) | 282 | 230 | 251 | 44 | |
| Cohort | <0.001* | ||||
| FHS | 137 (48.6%) | 70 (30.4%) | 0 (0%) | 2 (4.5%) | <0.05a,b,c,d,e,f |
| UNITE | 66 (23.4%) | 5 (2.2%) | 246 (98.0%) | 40 (90.9%) | <0.05a,b,c,d,e |
| BUADC | 79 (28.0%) | 155 (67.4%) | 5 (2.0%) | 2 (4.5%) | <0.05a,b,c,d,e |
| Age at death (S.E.M) | 74.6 (1.5) | 84.3 (0.7) | 59.7 (1.2) | 75.5 (1.7) | <0.001#,a,b,d,e,f |
| Sex %male | 176/106 (62.4%) | 135/95 (58.7%) | 251/0 (100%) | 43/1 (97.7%) | <0.001*b,c,d,e |
| RHI y/n ( %exposed) | 76/92 (45.2%) | 13/54 (19.4%) | 249/0 (100%) | 44/0 (100%) | <0.001*a,b,c,d,e |
| Exposure years (S.E.M.) | 4.12 (0.51) | 1.58 (0.50) | 16.1 (0.4) | 15.9 (1.4) | <0.001 #a,b,c,d,e |
| CAA with/without (% with) | 153/129 (54.3%) | 220/10 (95.7%) | 72/179 (28.7%) | 36/8 (81.8%) | <0.001*a,b,c,d,e,f |
| CAA severity score n (%) | <0.001* | ||||
| 1 | 98 (64.1%) | 86 (39.1%) | 49 (68.1%) | 13 (36.1%) | <0.05a,c,d,f |
| 2 | 44 (28.8%) | 84 (38.2%) | 15 (20.8%) | 15 (41.7%) | <0.05d |
| 3 | 11 (7.2%) | 50 (22.7%) | 8 (11.1%) | 8 (22.2%) | <0.05a,c |
| CTE stage % (n) | <0.001* | ||||
| Stage I | 37 (14.7%) | 3 (6.8%) | |||
| Stage II | 54 (21.5%) | 4 (9.1%) | |||
| Stage III | 97 (38.6%) | 11 (25.0%) | |||
| Stage IV | 63 (25.1%) | 26 (59.1%) | <0.05f | ||
| Neocortical LBD | 20/262 (7.1%) | 33/197 (14.3%) | 13/238 (5.2%) | 6/38 (13.6%) | 0.002*a,d, |
| Remote cortical microinfarcts | 74/173 (30.0%) | 62/149 (29.4%) | 28/189 (12.9%) | 7/29 (19.4%) | <0.001*b,d |
| Macro hemorrhages | 3/235 (1.3%) | 0/203 (0%) | 5/195 (2.5%) | 1/33 (2.9%) | 0.139* |
| Dementia | 73/157 (31.7%) | 172/18 (90.5%) | 123/109 (53.0%) | 36/2 (94.7%) | <0.001*a,b,c,d,f |
Data are presented as mean (S.E.M.) years for age at death and contact sports exposure and as # yes/# no (%) unless otherwise indicated. AD: Alzheimer disease; CTE: chronic traumatic encephalopathy; LBD: Lewy body disease; RHI: repetitive head impacts;
#
ANOVA with Bonferroni correction,
*
χ2 test for proportions between all pathology groups,
a
p<0.05 for comparison between No CTE/No AD and AD,
b
p<0.05 for comparison between No CTE/No AD and CTE,
c
p<0.05 for comparison between No CTE/No AD and CTE & AD,
d
p<0.05 for comparison between AD and CTE,
e
p<0.05 for comparison between AD and CTE & AD,
f
p<0.05 for comparison between CTE and CTE & AD